Fennec Pharmaceuticals Inc. (FRX.TO)

5.50 +0.49 (+9.78%) At close: 03:52PM EST

Fennec Pharmaceuticals Inc.

68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States
919 636 4530
http://www.fennecpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Rostislav Raykov	CEO & Director	430k	N/A	1976
Mr. Robert C. Andrade	Chief Financial Officer	311.75k	N/A	1975
Ms. Shubh Goel	Chief Commercial Officer	360k	N/A	1974
Mr. Mark Gowland	Controller	N/A	N/A	N/A
Mr. Lei Fang	Pres of Pharstat Inc	N/A	N/A	N/A
Ms. Anne McKay	Regulatory Consultant	N/A	N/A	1954
Mr. Alexander D. Smith M.S.	Consultant	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Corporate Governance

Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.